This is a prospective pilot protocol investigating whether ctDNA detection be improved by sampling the cancer draining vein versus the standard practice of sampling from a peripheral vein in patients who are undergoing biopsies for hepatobiliary and pancreatic cancers.
This is a, prospective single center pilot study to investigate whether ctDNA detection can be improved by sampling the cancer draining vein vs. a peripheral vein (current practice). As a secondary endpoint, both ctDNA results will be compared with percutaneous biopsy (standard of care).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
15
Blood collection to be obtained from peripheral vein and cancer draining vein during biopsy
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, United States
RECRUITINGComparison of the amount of ctDNA in draining vein plasma sample to peripheral vein sample through ratio of mean allele frequency
Ratio of mean allele frequency (MAF)% of hepatic or portal draining vein, and MAF% of peripheral blood will be utilized to compare the samples
Time frame: Up to 1 year
Number of unique alterations found in hepatic or portal vein plasma compared to number of alterations found in peripheral vein plasma
ctDNA results will be compared with percutaneous biopsy (standard of care)
Time frame: Up to 1 year
Number of unique alterations found in ctDNA compared to number of alterations derived next generation sequencing (NGS)
ctDNA results will be compared with percutaneous biopsy (standard of care)
Time frame: Up to 1 year
Chao Family Comprehensive Cancer Center University of California, Irvine
CONTACT
University of California Irvine Medical
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.